Save Sight Registries

Registries

- Macular Degeneration
- CNV other than wet AMD
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Keratoconus
- Glaucoma
- Ocular Oncology Blindness
- Uveitis

ICHOM Certified Supplier

Tools to

- Track and analyse patient and treatment outcomes
- Highlight treatment patterns that lead to improved patient outcomes
- Develop strategies to reduce the incidence of global blindness
- Lead scientific research collaboration

Graphical representation of visits over eight years
Right and Left eyes view



TO JOIN CONTACT:
SSR Research Officer
E: ssi.ssr@sydney.edu.au
T: +61 2 9382 7304

SSR Chief Investigator
Professor Mark Gillies
E: mark.gillies@sydney.edu.au

Keratoconus Chief Investigator
Professor Stephanie Watson
E: stephanie.watson@sydney.edu.au

Glaucoma Chief Investigator
Dr Mitchell Lawlor
E: mitchell.lawlor@sydney.edu.au

SAVE SIGHT INSTITUTE

THE UNIVERSITY OF SYDNEY



Patient specific graph with critical data to facilitate and expedite clinical decision making during patient visits.

The figure shows the course of a patient who was being treated for DME in both eyes with bevacizumab. When visual acuity declined in association with increasing macular thickness, the patient was switched to aflibercept. This resulted in improved vision, and reduced swelling with drying of the fovea although he still required 2 monthly injections.

This graph shows the journey of a patient with keratoconus. Over time their vision declined in each eye and keratometry increased. Corneal cross-linking was performed (treatment) which stabilized keratometry and vision.

SSR is a scientific collaboration nationally and internationally which aims to develop benchmarks and drive improved patient outcomes. The Registries provide evidence for real world effectiveness of existing and new treatments, highlighting treatment patterns that lead to the best outcomes for patients.